SFTPB Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P07988 |
---|---|
Clone Names | 100427199 |
Gene ID | 6439 |
---|---|
Other Names | Pulmonary surfactant-associated protein B, SP-B, 18 kDa pulmonary-surfactant protein, 6 kDa protein, Pulmonary surfactant-associated proteolipid SPL(Phe), SFTPB, SFTP3 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SFTPB |
---|---|
Synonyms | SFTP3 |
Function | Pulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter. |
Cellular Location | Secreted, extracellular space, surface film. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SFTPB is the pulmonary-associated surfactantprotein B (SPB), an amphipathic surfactant protein essential forlung function and homeostasis after birth. Pulmonary surfactant isa surface-active lipoprotein complex composed of 90% lipids and 10%proteins which include plasma proteins and apolipoproteins SPA,SPB, SPC and SPD. The surfactant is secreted by the alveolar cellsof the lung and maintains the stability of pulmonary tissue byreducing the surface tension of fluids that coat the lung. The SPBenhances the rate of spreading and increases the stability ofsurfactant monolayers in vitro. Multiple mutations in this genehave been identified, which cause pulmonary surfactant metabolismdysfunction type 1, also called pulmonary alveolar proteinosis dueto surfactant protein B deficiency, and are associated with fatalrespiratory distress in the neonatal period. Alternatively splicedtranscript variants encoding the same protein have been identified.
References
Baekvad-Hansen, M., et al. Eur. Respir. J. (2010) In press :Kim, W.J., et al. Eur. Respir. J. (2010) In press :Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010)Cho, M.H., et al. Respir. Res. 11, 30 (2010) :Chaiworapongsa, T., et al. J. Matern. Fetal. Neonatal. Med. 21(9):663-670(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.